Medical Research Council

United Kingdom Research and Innovation

University of Leicester

Julian Edward Sale

Michael S Neuberger

Nicolas Phillip James Brindle

Sarah Jane Cumbers

Shunichi Takeda

Shunichi Department Of Radiation Genetics Takeda

Michael Samuel Neuberger

Nicolas Phillip Brindle

In one aspect, provided herein is a polypeptide comprising a modified angiopoietin receptor or fragment thereof, wherein the polypeptide binds preferentially to angiopoietin-2 compared to angiopoeitin-1. Nucleic acid sequences encoding the polypeptide, as well as pharmaceutical uses of the polypeptide in treating diseases such as cancer and inflammation are also provided.

Nucleic acid encoding angiopoietin-2 specific Tie2 receptor

In one aspect, provided herein is a polypeptide comprising a modified angiopoietin receptor or fragment thereof, wherein the polypeptide binds preferentially to angiopoietin-2 compared to angiopoietin-1. Nucleic acid sequences encoding the polypeptide, as well as pharmaceutical uses of the polypeptide in treating diseases such as cancer and inflammation are also provided.

Angiopoietin-2 specific TIE2 receptor

The invention relates to a method for preparing an antibody-producing cell line capable of directed constitutive hypermutation of a specific nucleic acid region, comprising the steps of: a) screening a clonal cell population for V gene diversity; b) isolating one or more cells which display V gene diversity and comparing the rate of accumulation of mutations in the V genes and other genes of the selected cells; and c) selecting a cell in which the rate of V gene mutation exceeds that of other gene mutation.

Method for generating diversity

Growing community of inventors

Cambridge, United Kingdom

Julian Edward Sale